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Multidrug resistance (MDR) of tumour cells is considered to
be one of the major obstacles to effective cancer chemo-
therapy (Curt et al., 1984; Bradley et al., 1988; van der Bliek
& Borst, 1989). Such resistance can be an intrinsic property
of a tumour or may be acquired following courses of
chemotherapy. MDR has been shown to be associated with
reduced intracellular drug content due to the over-expression
of the P-glycoprotein (P-170), an energy dependent efflux
pump that prevents intracellular accumulation of antineo-
plastic drugs (Juliano & Ling, 1976).
Since many mechanisms for the development of MDR are
associated with energy metabolism pathways, the high
aerobic glycolysis rate showed by resistant cells (Lyon et al.,
1988; Kaplan et al., 1990) could make them targets for drugs
inhibiting the energy metabolism.
Lonidamine (LND, Angelini ACRAF, Pomezia, Rome,
Italy), a dichlorinated derivative of indazole-3-carboxylic
acid, has been proven to strongly influence the energy
metabolism of neoplastic cells inhibiting their aerobic lactate
production (Floridi & Lehninger, 1983). LND appears also
to be able to induce wide changes in plasma membrane due
to its high affinity for the inner leaflet of the lipid bilayer
(Malorni et al., 1988). Both the main LND effects, the reduc-
tion of ATP production and the membrane damage, could
impair the metabolic adaptations associated with the
development of drug resistance.
Previous data obtained in our laboratory demonstrated
that LND differently affected the cell survival of melanoma
lines and when used in combination with ADR determined a
synergistic effect, according to the sequence employed (Zupi
et al., 1986). Recently, it was reported that LND also
enhanced the cytotoxic effect of cis-platinum on a human
squamous cell carcinoma (Raaphorst et al., 1990). Moreover,
when combined with radiation LND potentiates the lethal
effect of ionising radiation on fibrosarcoma tumour cells
(Kim et al., 1984).
In the present study we have investigated the efficacy of
LND given in combination with Adriamycin (ADR, Adri-
blastina, Farmitalia Carlo Erba, Milano, Italy) on a human
breast cancer cell line, MCF-7 wild type, and its derivative
ADR-resistant line MCF-7 ADRR.
Both tumour lines (MCF-7 WT and MCF-7 ADRR, kindly
provided by Dr K. Cowan from NCI, Bethesda, Maryland,
USA) were maintained as monolayer cultures in 25 cm2 Corn-
ing flasks in supplemented RPMI 1640 medium (Gibco).
ADRR cells were grown in medium containing 10JiM ADR
and passaged for at least 2-4 weeks in medium lacking the
drug prior to their use in experiments. WT and ADRR cells
were exposed to ADR (from 0.01 to 50 JAM) alone and in
combination with a non-cytotoxic dose of LND (50 fig ml-'),
tested in preliminary experiments.
1 x 106 ADRR and WT cells were plated in 25 cm2 Corning
flasks in supplemented RPMI 1640 medium. The next day,
medium containing the varying concentration of drug was
added to the cells. After 7 days, the cells were harvested,
assayed for cell viability (Trypan Blue exclusion test) and
counted (Coulter Counter, Kontron, model, ZM). Drug sen-
sitivity was evaluated by calculating the ADR dose that
caused 50% of growth inhibition (ICy, value). Samples from
cells exposed for different times to ADR or to ADR + LND
were twice washed in PBS and kept frozen (106 cells ml-') for
intracellular ADR determination.
Purified specific anti-ADR IgGs from polyclonal anti-ADR
immune serum were employed to determine the intracellular
ADR content as previously described (Citro et al., 1988).
Briefly, the assay was performed by a competitive ELISA
using a suspension from treated cells in cold PBS (106 cells
ml-' sonicated at 100 W for 1 min). Experimental data were
compared using Student's t-test, and the results were con-
sidered statistically significant when P <0.05.
The sensitivity of both cell lines to ADR and to
ADR + LND exposures is reported in Table I. WT and
ADRR MCF-7 cells showed a marked difference in the ICm
value following exposure to ADR: 0.03 and 9 JAM, respec-
tively. The simultaneous exposure to both drugs
(ADR + LND) enhanced the ADR lethal effect, as shown by
the decrease in the IC50 values in both tumour lines. How-
ever, the enhancement of ADR cytotoxicity induced by LND
is more significant for ADRR cells than for their ADR-
sensitive counterparts. The ICm value of sensitive cells treated
with the combination ARD + LND fell to 0.008 gM (about a
4-fold decrease of that observed in ADR alone treated cells)
while the ADR dose able to kill 50% of the ADRR cells
exposed to both agents fell to 0.007 JM (about a 1,300-fold
decrease). The selectivity elicited by LND on the ADR-
resistant cell line appeared also by the significant decrease in
the resistance index (0.875 for ADR + LND exposure vs 300
for ADR exposure).
Tables II and III show the intracellular ADR content in
both tumour lines upon ADR and ADR + LND treatments.
In order to compare cellular ADR content and drug activity,
the corresponding cell surviving fractions were also reported.
The results are expressed as the mean ± s.e. of three separate
determinations. Remarkably, differences in ADR intracellular
content were observed between the two MCF-7 cell lines.
In the sensitive cell line treated with ADR as a single
agent, an increase of the ADR intracellular content as a
function of both dose and exposure time was observed (Table
II). The statistical analysis performed comparing the ADR
content for each dose at the same exposure time demon-
strated that there was a significant difference between each
dose, with a P value ranging from 0.0002 to 0.04. A statis-
tical significance was also obtained comparing the ADR
content for each exposure time at the same dose (P value
ranging from 0.0002 to 0.03).
Otherwise, in the resistant line treated with ADR alone the
intracellular ADR content was not significantly modified by
increasing both the dose and the exposure time (Table III).
In fact, the intracellular ADR contents analysed either in
function of doses or times did not significantly differ (P
values = 0.05-0.55). Significant differences were only
observed comparing the intracellular ADR content at the
lowest and highest ADR doses (0.0007 <P value <0.01)
and exposure times (0.003 <P value <0.03).
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Table I Enhancement of ADR-induced cytotoxicity by Lonidamine
in MCF-7 WT and MCF-7 ADRR cells
IC50 (JIM) Resistance
Drug MCF-7 WT MCF-7 ADRR index
ADR 0.030 + 0.012 9.000 + 0.500 300
ADR + LND 0.008 0.001 0.007 + 0.001 0.875
Cytotoxicity of ADR in the presence and absence of LND, at a
non-cytotoxic dose, was measured by determining the mean IC50
values ± s.e. obtained from at least two separate experiments, each
done in triplicate. Resistance index was calculated by dividing the
IC" values of the resistant line by those of the parental line.
Figure 1 shows the intracellular ADR content of the two
cell lines treated with the highest ADR dose as a function of
exposure time. The trend of the two curves illustrates the
different behaviour showed by the sensitive and the resistant
lines. ADR concentration in WT cells increased steadily
reaching the value of 78 ng ADR 10-6 cells within 72 h. On
the contrary, in ADRR cells no marked increase in the drug
content was observed during the treatment. These results
demonstrate that the accumulation rate is consistently
reduced in ADRR cells, indicating that the increase of drug
doses and exposure times could be uneffective on drug-
resistant tumour cells.
The ADR + LND combination differentially influenced the
intracellular ADR accumulation of the two cell lines em-
ployed. Sensitive cells treated with the combination (Al, B1,
Cl, D1; Table II) showed values ofdrug concentration similar
to those obtained after their exposure to ADR as a single
agent (A, B, C, D; Table II). In fact as also demonstrated by
the statistical analysis, the differences in ADR content
between the two treatments were not statistically significant.
These data correlate with the cell response to the combina-
tion; ADR + LND gave rise to a moderate enhancement of
ADR cytotoxicity, as shown by the values of cell survival
reported in Table II.
On the contrary, the ADR + LND association strongly
affected the intracellular ADR accumulation of the resistant
cells. In fact, the presence of LND nearly allowed to double
the intracellular ADR content for all doses and exposure
times employed. The differences of intracellular ADR level
detected between the two treatments came out highly
significant from the statistical analysis (A, B, C, D vs Al, B1,
Cl, D1; Table III).
Comparing the data reported in Tables II and III, it
appears that the combination allowed ADR to achieve in the
resistant cells an intracellular amount similar to that
obtained for the wild type cells, indicating that LND had the
ability to restore the in vitro sensitivity of ADR-resistant
cells. In particular, LND allows ADR to reach the same
intracellular content otherwise achievable with a 1,000-fold
higher ADR dose given as single agent (Table III). The
values of cell survival demonstrate the ability 'of LND to
overcome ADR resistance (Table III). This effect is partic-
ularly relevant since at the lowest ADR dose, uneffective on
the resistant cells, the combination determines a remarkable
increase in cell lethality. In conclusion, these results indicate
that the combination ADR + LND could be useful to imp-
rove the therapeutic index of ADR treatment.
The enhancement of the ADR cytotoxicity observed on the
MCF-7 ADRR cells could be the result of two simultaneous
selective LND effects: (1) the LND-lipid bilayer interactions
give rise to clustering of intrinsic intramembrane proteins like
P-170 glycoprotein, which is present on the MCF-7 ADRR
cell membranes (Fairchild et al., 1987), impairing its
biological functions and thus reducing drug efflux and
detoxification; (2) Lonidamine specifically inhibits the activity
of mitochondria bound hexokinase (Floridi et al., 1989)
affecting the aerobic glycolysis of tumour cells. Since ADRR
cells show an enhanced rate of glycolysis (3-fold), as com-
pared to drug sensitive cells (Kaplan et al., 1990), LND
could selectively impair cellular energy-dependent mechan-
isms like drug efflux, drug-conjugation, enzyme synthesis,
and lethal damage recovery.
Table II Intracellular ADR content and surviving fractions of MCF-7 WT cells exposed to ADR or to
the association ADR + LND
Intracellular ADR content' (ng ADR 10-6 cells) Surviving cells'
Treatment I h 12h 24h 72h (% of control)
(A) ADR 0.01 pLM 24.0 3.4 27.4 3.0 30.0 3.0 45.3 ±3.2 46 2.0
(Al) ADR 0.01 p4M + LNDC 27.0 ± 1.6 30.0 ± 2.2 34.0 ± 1.5 46.0 ± 3.0 24 ± 1.5
(B) ADR 0.1I M 27.5 2.7 29.4 1.4 32.2 3.4 50.0 2.3 30 2.2
(B1) ADR 0.1 jAM + LND 28.0 2.9 35.0 1.8 36.0 3.2 56.0 2.5 21 ± 1.5
(C) ADR 1 jAM 33.0 2.6 42.0 4.0 45.5 3.2 67.0 4.0 23 1.6
(C1) ADR 1 jiM + LND 35.0 ± 3.1 42.0 ± 2.6 44.0 ± 3.4 68.0 ± 3.4 15 ± 1.7
(D) ADR 10 lM 42.5 3.5 49.0 4.9 59.0 3.5 78.0 3.5 18 1.2
(DI) ADR 1O1LM+ LND 40.0 2.6 44.5 3.0 57.0±4.0 72.0 2.3 12± 1.5
0ADR content was evaluated at different doses and after different exposure times (1, 12, 24, 72 h).
'Surviving fractions were determined at the end of the experiment. CLND = 50figml-' percent survival
of LND treated cells was 95 ± 0.6. Not statistically different: A vs A1 P <0.8; B vs B, P < 0.9; C vs C,
P <0.8; D vs Di P <0.5.
Table III Intracellular ADR content and surviving fractions of MCF-7 ADRR cells exposed to ADR or
to the association ADR + LND
Intracellular ADR content' (ng ADR 10-6 cells) Surviving cells'
Treatment I h 12h 24h 72h (% of control)
(A) ADR 0.01 I1M 12.0 1.8 14.0 2.5 18.0 1.4 22.0 2.7 100 1.1
(A1) ADR 0.01 IJM + LNDC 21.0 ± 1.7 25.0 ± 2.0 28.5 ± 2.0 33.0 ± 2.0 12 ± 1.9
(B) ADR 0.01 jiM 15.0 2.0 20.5 1.6 22.0 1.5 25.0 2.9 94 0.8
(B1) ADR 0.1IjM + LND 29.0 2.2 33.0 2.6 35.0 2.4 38.0 1.5 11 ± 1.5
(C) ADR 1 jAM 18.0 1.4 22.5 ± 1.4 25.0 1.2 28.0 2.3 92 3.0
(C1) ADR 1 jAM + LND 33.0 1.4 35.0 1.6 38.0 1.0 39.5 ± 1.9 7 1.1
(D) ADR 1O0iM 25.0 2.1 27.0± 1.3 29.5± 1.6 30.0± 1.8 48± 1.0
(DI) ADR 10 AM+ LND 37.0 2.0 39.0± 1.7 42.0 2.0 45.0± 1.9 6 0.6
0ADR content was evaluated at different doses and after different exposure times (1, 12, 24, 72 h).
'Surviving fractions were determined at the end of the experiment. CLND = 50 lagml-' percent survival
of LND treated cells was 94 ± 0.4. Statistically different: A vs A1 P K0.005; B vs B, P <0.006; C vs C,
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Figure I Uptake of 10f1m ADR in (-) MCF-7 WT and (A)
MCF-7 ADR' cells. Drug uptake was evaluated at different
periods of time. Each point is the mean ± s.e of three separate
determinations.
The relationship between the high rate ofaerobic glycolysis
and drug resistance of MCF-7 ADRR cells was recently
demonstrated by Kaplan et al. using 2-deoxyglucose, a
specific glycolysis inhibitor. This drug was found to be ex-
tremely toxic for the cells which had acquired resistance to
Adriamycin (Kaplan et al., 1990). These data are in agree-
ment with our results, demonstrating that a specific inhibitor
of aerobic glycolysis like Lonidamine can play a remarkable
role to reduce or overcome multidrug resistance.
In conclusion, the present study indicates the possibility to
use Lonidamine as potentiating agent to interfere with MDR
properties. Considering its good tolerance reported in
preliminary clinical trials (Ozols et al., 1983; Evans et al.,
1984; Pronzato et al., 1989) Lonidamine, in combination with
antitumour drugs, could improve cancer therapy when
tumours initially responsive to chemotherapy develop resist-
ance to the drugs following treatment with one of them.
This work was partially supported by grants from 'Ministero della
Sanita' and AIRC (Italian Association for Cancer Research).
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